HMR lignans are a concentrated, quickly absorbed plant compound from Norway spruce. The body converts them into an active compound linked to healthier aging. Supplements reliably raise this compound and, in one small study, eased menopausal hot flashes. Broader benefits for hormone-related cancers, heart, and metabolic health remain preliminary. Safety appears favorable, with mild, mostly theoretical concerns. (Full Review)

Protocol

Dose

36–72 mg/day

Standardized HMR; start near 36 mg/day and assess tolerance

Timing

Once daily

Take with a consistent daily meal to aid tolerability

Formulation

Standardized 7-HMR

Defined lignan content, not crude spruce extract

Time to effect

Enterolactone rise

Hours–days

Blood enterolactone rises within hours to days of first doses

Hot flashes

Several weeks

Symptom relief measured over weeks of continued use

Peak levels

~1–24 h

Parent peaks ~1 h; enterolactone peaks ~24 h

Benefits

Medium: Elevation of blood enterolactone

Low: Reduction of menopausal hot flashes; breast cancer risk and prognosis support; cardiovascular and overall mortality support; prostate cancer protection

Speculative: Metabolic syndrome, weight, and glucose regulation; neuroprotection; anti-inflammatory and antioxidant / vascular protection

Contraindications

Active estrogen-receptor-positive breast, uterine, or ovarian cancer

Pregnancy or breastfeeding

Children

Hormone-modulating cancer therapy (without oncology input)

Key Interactions

Hormone therapies and SERMs (tamoxifen, raloxifene)

Aromatase inhibitors (letrozole, anastrozole, exemestane)

5-alpha-reductase inhibitors (finasteride, dutasteride)

Anticoagulant and antiplatelet drugs (warfarin, aspirin, clopidogrel)

Antidiabetic medications (metformin, insulin, sulfonylureas)

Phytoestrogen supplements (soy isoflavones, flax SDG lignans, red clover, DIM)

Additive hormone-modulating supplements (saw palmetto, stinging nettle root, flax lignans)

Iron supplements

Risk & Side Effects

Low: Mild estrogenic activity; gastrointestinal discomfort

Speculative: Theoretical growth stimulation in estrogen-receptor-positive cancers; additive effects with hormone-modulating drugs; unknown safety in pregnancy and breastfeeding

Monitoring

Marker	Target	Why
Serum enterolactone	Higher within assay range (>20–30 nmol/L)	Confirms HMR is being converted to its active metabolite
hs-CRP	< 1.0 mg/L	Tracks the anti-inflammatory hypothesis
Fasting insulin	2–5 µIU/mL	Screens the metabolic/insulin-resistance hypothesis
Lipid panel (LDL, triglycerides)	LDL < 100 mg/dL; triglycerides < 100 mg/dL	Captures the lipid effects seen in animal data
PSA (men)	< 1.0 ng/mL (age-dependent)	Standard prostate surveillance for male users
Estradiol / hormone panel	Age- and sex-appropriate	Contextualizes the weak hormonal activity

Cadence: Baseline, then recheck at 8–12 weeks to confirm response and tolerability, then every 6–12 months during continued use

Qualitative Assessment

Frequency and severity of menopausal hot flashes and night sweats
General energy levels and sense of wellbeing
Digestive comfort and bowel regularity
Sleep quality, particularly where night-time symptoms were disruptive

HMR Lignans for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment